AGER monoclonal antibody, clone 1C5
* The price is valid only in USA. Please select country.
-
More Files
- More Functions
-
Specifications
Product Description
Mouse monoclonal antibody raised against recombinant AGER.
Immunogen
Recombinant protein corresponding to human AGER.
Host
Mouse
Reactivity
Human
Form
Liquid
Isotype
IgG1, kappa
Quality Control Testing
Antibody Reactive Against Recombinant Protein.
Recommend Usage
Western Blot (0.1 ug/mL)
Immunocytochemistry (1 ug/mL)
ELISA (0.1 ug/mL)
Flow Cyt (1 ug/mL)
The optimal working dilution should be determined by the end user.Storage Buffer
In PBS (0.1% proclin, 2.0% Block Ace)
Storage Instruction
Store at -20°C.
Aliquot to avoid repeated freezing and thawing. -
Applications
Western Blot (Cell lysate)
Western blot analysis of extract from CHO cells, using AGER monoclonal antibody, clone 1C5 (Cat # MAB1724) .Immunocytochemistry
Immunocytochemistry analysis of CHO cells overexpressing human AGER, using AGER monoclonal antibody, clone 1C5 (Cat # MAB1724) .Enzyme-linked Immunoabsorbent Assay
Flow Cytometry
-
Gene Info — AGER
Entrez GeneID
177Gene Name
AGER
Gene Alias
MGC22357, RAGE
Gene Description
advanced glycosylation end product-specific receptor
Omim ID
600214Gene Ontology
HyperlinkGene Summary
This gene encodes a member of the immunoglobulin superfamily of cell surface molecules. It is a receptor for various molecules, including the amyloidogenic form of serum amyloid A, amyloid-beta protein, members of the S100/calgranulin superfamily and advanced glycation end products. The gene lies within the major histocompatibility complex (MHC) class III region on chromosome 6. Alternative splicing results in two transcript variants encoding different isoforms. [provided by RefSeq
Other Designations
OTTHUMP00000029155|OTTHUMP00000029156|advanced glycosylation end product-specific receptor RAGE3|advanced glycosylation end product-specific receptor variant sRAGE1|advanced glycosylation end product-specific receptor variant sRAGE2|receptor for advanced
-
Interactomes
-
Diseases
-
Publication Reference
-
RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases.
Koyama H, Yamamoto H, Nishizawa Y.
Molecular Medicine (Cambridge, Mass.) 2007 Nov; 13(11-12):625.
Application:ELISA, Human, Human plasma.
-
The amphoterin (HMGB1)/receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness. Functional inactivation of RAGE in L6 myoblasts results in tumor formation in vivo.
Riuzzi F, Sorci G, Donato R.
The Journal of Biological Chemistry 2006 Mar; 281(12):8242.
-
Acute lung injury as an adverse event of gefitinib.
Inomata S, Takahashi H, Nagata M, Yamada G, Shiratori M, Tanaka H, Satoh M, Saitoh T, Sato T, Abe S.
Anti-Cancer Drugs 2004 Jun; 15(5):461.
-
Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury.
Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, Yasui K, Takeuchi M, Makita Z, Takasawa S, Okamoto H, Watanabe T, Yamamoto H.
The Biochemical Journal 2003 Mar; 370(Pt 3):1097.
Application:WB-Tr, Monkey, COS-7 cells.
-
Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases.
Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Ingram M, Lu A, Tanaka H, Hori O, Ogawa S, Stern DM, Schmidt AM.
Nature 2000 May; 405(6784):354.
Application:IF, WB-Ce, Mouse, Rat, Lung murine carcinoma, C6 glioma cells.
-
RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases.
- +1-909-264-1399
+1-909-992-0619
Toll Free : +1-877-853-6098 - +1-909-992-3401
- sales@abnova.com